Medicure Inc (MCUJF) 1.4930 $MCUJF
Medicure provides quarterly revenue on a calendar basis following change to year end
PR Newswire - Mon Feb 02, 9:00AM CST
Medicure Inc. ("Medicure" or the "Company"
(TSXV:MPH, OTCQB:MCUJF), a specialty pharmaceutical company, today provided detail on its historic calendar quarter revenue in anticipation of future reporting under the new financial reporting periods. This change in year end from May 31 to December 31 was previously announced on December 18, 2014.
MPH.VN: 1.870 (+0.260)
Medicure announces shares for debt settlements
PR Newswire - Tue Jan 27, 3:16PM CST
Medicure Inc. (the "Company" (TSXV:MPH, OTC:MCUJF.US) announces today that the Company, subject to all necessary regulatory approvals, has entered into shares for debt agreements with certain members of the Board of Directors and a consultant, pursuant to which the Company will issue 108,206 of its common shares at a deemed price of $1.44 per common share to satisfy $155,816.64 of outstanding amounts owing to these individuals. These settlements do not include Dr. Albert Friesen, Chair and Chief Executive Officer of the Company. The shares will be subject to resale restrictions for a period of four months from the date of issuance under applicable securities legislation.
MPH.VN: 1.870 (+0.260)
Medicure announces issuance of shares under previously announced shares for debt settlement
CNW Group - Fri Jan 09, 3:35PM CST
Medicure Inc. (the "Company" (TSXV:MPH, OTC:MCUJF.US) announces today that the Company has issued 205,867 of its common shares at a deemed price of $1.98 per common share extinguishing $407,616.66 of amounts owing to its Chief Executive Officer, Dr. Albert Friesen and certain members of the Board of Directors under shares for debt agreements originally entered into and announced on July 11, 2014. These shares will be subject to resale restrictions for a period of four months from the date of issuance under applicable securities legislation.
MPH.VN: 1.870 (+0.260)
Medicure Announces Change in Fiscal Year End and Provides One-Time Guidance on Quarterly Revenue
PR Newswire - Thu Dec 18, 12:24PM CST
Medicure Inc. ("Medicure" or the "Company" (TSXV:MPH, OTCQB:MCUJF), a specialty pharmaceutical company, today announced that the Board of Directors has approved a change in the Company's fiscal year end to December 31. The change will result in a stub period from June 1, 2014, to December 31, 2014, and as a result of the change, the first full fiscal year will end on December 31, 2015. This change in year end from May 31 to December 31 is being made by the Company to better align the Company's financial reporting calendar with its industry peers and with most other companies trading on the TSX.V.
MPH.VN: 1.870 (+0.260)
Dr. Albert D. Friesen to File Early Warning Report
Marketwired - Wed Nov 05, 11:34AM CST
Medicure Inc. ("Medicure" or the "Company" (TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, today reports that since March 1, 2013 Dr. Albert D. Friesen has acquired 299,308 common shares which exceeds 2% of the outstanding common shares of Medicure. This 2% reporting threshold was reached on November 4, 2014 with the acquisition of 150,408 common shares of Medicure representing approximately 1.22% of the Company's outstanding common shares (the "Acquisition" . The shares, which are still subject to approval of the TSX Venture Exchange ("TSXV" , will be issued by the Company at a deemed price of $1.98 per share in order to settle outstanding fees payable to Dr. Friesen for past services rendered to the Company up to July 11, 2014 (the "Settlement" . The Settlement was approved by the disinterested shareholders of the Company at its annual and special meeting of shareholders held on November 4, 2014. Dr. Friesen may in the future acquire additional shares in the Company, if deemed appropriate to do so in his sole discretion.
MPH.VN: 1.870 (+0.260)
Medicure net income positive in Q3
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 5:06PM CDT
Medicure Reports Financial Results for the First Quarter Fiscal 2015
Marketwired - Thu Oct 16, 4:21PM CDT
Medicure Inc. ("Medicure" or the "Company" (TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, today reported its results from operations for the quarter ended August 31, 2014.
MPH.VN: 1.870 (+0.260)
Medicure Reports Financial Results for Fiscal 2014
Marketwire - Wed Sep 10, 4:06PM CDT
Medicure Inc. ("Medicure" or the "Company" (TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, today reported its results from operations for the fiscal year ended May 31, 2014.
MPH.VN: 1.870 (+0.260)
Medicure Provides Update on Tardoxal and TEND-TD Study
Marketwire - Wed Aug 13, 11:23AM CDT
Medicure Inc. ("Medicure" or the "Company" (TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, announces that the preliminary results of its Phase IIa Clinical Trial, Tardoxal(TM) for the Treatment of Tardive Dyskinesia (TEND-TD) showed a non-statistically significant improvement in the primary efficacy endpoint in patients treated with Tardoxal. Medicure views these preliminary results as supportive of continuing the program and developing a modified formulation as a prelude to a larger, confirmatory Phase II study.
MPH.VN: 1.870 (+0.260)
Medicure Announces Shares for Debt Settlement
Marketwire - Fri Jul 11, 1:59PM CDT
Medicure Inc. (the "Company" (TSX VENTURE: MPH)(OTCQB: MCUJF) announces today that the Company, subject to all necessary regulatory approvals, has entered into shares for debt agreements with its Chief Executive Officer, Dr. Albert Friesen and certain members of the Board of Directors, pursuant to which the Company will issue 205,867 of its common shares at a deemed price of $1.98 per common share to satisfy $407,616.66 of outstanding amounts owing to Dr. Friesen and members of the Company's Board of Directors. These shares will be subject to resale restrictions for a period of four months from the date of issuance under applicable securities legislation.
MPH.VN: 1.870 (+0.260)
Medicure Announces Grant of Options
Marketwire - Mon Jul 07, 3:31PM CDT
Medicure Inc. (the "Company" (TSX VENTURE: MPH)(OTCQB: MCUJF) announces today that its Board of Directors has approved the grant of an aggregate of 332,300 options to certain directors, officers, employees, management company employees and consultants of the Company pursuant to the Company's Stock Option Plan. Of these options, 92,300 are set to expire on the tenth anniversary of the date of grant, and 240,000 are set to expire on the fifth anniversary of the date of grant. All 332,300 options were issued at an exercise price of $1.90 per share. The options are subject to the approval of the TSX Venture Exchange.
MPH.VN: 1.870 (+0.260)
Medicure provides quarterly revenue on a calendar basis following change to year end
PR Newswire - Mon Feb 02, 9:00AM CST
Medicure Inc. ("Medicure" or the "Company"
(TSXV:MPH, OTCQB:MCUJF), a specialty pharmaceutical company, today provided detail on its historic calendar quarter revenue in anticipation of future reporting under the new financial reporting periods. This change in year end from May 31 to December 31 was previously announced on December 18, 2014. MPH.VN: 1.870 (+0.260)
Medicure announces shares for debt settlements
PR Newswire - Tue Jan 27, 3:16PM CST
Medicure Inc. (the "Company"
(TSXV:MPH, OTC:MCUJF.US) announces today that the Company, subject to all necessary regulatory approvals, has entered into shares for debt agreements with certain members of the Board of Directors and a consultant, pursuant to which the Company will issue 108,206 of its common shares at a deemed price of $1.44 per common share to satisfy $155,816.64 of outstanding amounts owing to these individuals. These settlements do not include Dr. Albert Friesen, Chair and Chief Executive Officer of the Company. The shares will be subject to resale restrictions for a period of four months from the date of issuance under applicable securities legislation. MPH.VN: 1.870 (+0.260)
Medicure announces issuance of shares under previously announced shares for debt settlement
CNW Group - Fri Jan 09, 3:35PM CST
Medicure Inc. (the "Company"
(TSXV:MPH, OTC:MCUJF.US) announces today that the Company has issued 205,867 of its common shares at a deemed price of $1.98 per common share extinguishing $407,616.66 of amounts owing to its Chief Executive Officer, Dr. Albert Friesen and certain members of the Board of Directors under shares for debt agreements originally entered into and announced on July 11, 2014. These shares will be subject to resale restrictions for a period of four months from the date of issuance under applicable securities legislation. MPH.VN: 1.870 (+0.260)
Medicure Announces Change in Fiscal Year End and Provides One-Time Guidance on Quarterly Revenue
PR Newswire - Thu Dec 18, 12:24PM CST
Medicure Inc. ("Medicure" or the "Company"
(TSXV:MPH, OTCQB:MCUJF), a specialty pharmaceutical company, today announced that the Board of Directors has approved a change in the Company's fiscal year end to December 31. The change will result in a stub period from June 1, 2014, to December 31, 2014, and as a result of the change, the first full fiscal year will end on December 31, 2015. This change in year end from May 31 to December 31 is being made by the Company to better align the Company's financial reporting calendar with its industry peers and with most other companies trading on the TSX.V. MPH.VN: 1.870 (+0.260)
Dr. Albert D. Friesen to File Early Warning Report
Marketwired - Wed Nov 05, 11:34AM CST
Medicure Inc. ("Medicure" or the "Company"
(TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, today reports that since March 1, 2013 Dr. Albert D. Friesen has acquired 299,308 common shares which exceeds 2% of the outstanding common shares of Medicure. This 2% reporting threshold was reached on November 4, 2014 with the acquisition of 150,408 common shares of Medicure representing approximately 1.22% of the Company's outstanding common shares (the "Acquisition" . The shares, which are still subject to approval of the TSX Venture Exchange ("TSXV" , will be issued by the Company at a deemed price of $1.98 per share in order to settle outstanding fees payable to Dr. Friesen for past services rendered to the Company up to July 11, 2014 (the "Settlement" . The Settlement was approved by the disinterested shareholders of the Company at its annual and special meeting of shareholders held on November 4, 2014. Dr. Friesen may in the future acquire additional shares in the Company, if deemed appropriate to do so in his sole discretion. MPH.VN: 1.870 (+0.260)
Medicure net income positive in Q3
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 5:06PM CDT
Medicure Reports Financial Results for the First Quarter Fiscal 2015
Marketwired - Thu Oct 16, 4:21PM CDT
Medicure Inc. ("Medicure" or the "Company"
(TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, today reported its results from operations for the quarter ended August 31, 2014. MPH.VN: 1.870 (+0.260)
Medicure Reports Financial Results for Fiscal 2014
Marketwire - Wed Sep 10, 4:06PM CDT
Medicure Inc. ("Medicure" or the "Company"
(TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, today reported its results from operations for the fiscal year ended May 31, 2014. MPH.VN: 1.870 (+0.260)
Medicure Provides Update on Tardoxal and TEND-TD Study
Marketwire - Wed Aug 13, 11:23AM CDT
Medicure Inc. ("Medicure" or the "Company"
(TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, announces that the preliminary results of its Phase IIa Clinical Trial, Tardoxal(TM) for the Treatment of Tardive Dyskinesia (TEND-TD) showed a non-statistically significant improvement in the primary efficacy endpoint in patients treated with Tardoxal. Medicure views these preliminary results as supportive of continuing the program and developing a modified formulation as a prelude to a larger, confirmatory Phase II study. MPH.VN: 1.870 (+0.260)
Medicure Announces Shares for Debt Settlement
Marketwire - Fri Jul 11, 1:59PM CDT
Medicure Inc. (the "Company"
(TSX VENTURE: MPH)(OTCQB: MCUJF) announces today that the Company, subject to all necessary regulatory approvals, has entered into shares for debt agreements with its Chief Executive Officer, Dr. Albert Friesen and certain members of the Board of Directors, pursuant to which the Company will issue 205,867 of its common shares at a deemed price of $1.98 per common share to satisfy $407,616.66 of outstanding amounts owing to Dr. Friesen and members of the Company's Board of Directors. These shares will be subject to resale restrictions for a period of four months from the date of issuance under applicable securities legislation. MPH.VN: 1.870 (+0.260)
Medicure Announces Grant of Options
Marketwire - Mon Jul 07, 3:31PM CDT
Medicure Inc. (the "Company"
(TSX VENTURE: MPH)(OTCQB: MCUJF) announces today that its Board of Directors has approved the grant of an aggregate of 332,300 options to certain directors, officers, employees, management company employees and consultants of the Company pursuant to the Company's Stock Option Plan. Of these options, 92,300 are set to expire on the tenth anniversary of the date of grant, and 240,000 are set to expire on the fifth anniversary of the date of grant. All 332,300 options were issued at an exercise price of $1.90 per share. The options are subject to the approval of the TSX Venture Exchange. MPH.VN: 1.870 (+0.260)
